-
Mashup Score: 6
SAN FRANCISCO — “It’s been a fantastic ride. I’ve enjoyed every moment of it,” Refiloe Masekela, MD, PhD, chair of the Pan African Thoracic Society, told Healio at the American Thoracic Society International Conference. Masekela was on hand to receive ATS’s World Lung Health Award in recognition of her lengthy career, which includes founding the African Chronic
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 6
SAN FRANCISCO — “It’s been a fantastic ride. I’ve enjoyed every moment of it,” Refiloe Masekela, MD, PhD, chair of the Pan African Thoracic Society, told Healio at the American Thoracic Society International Conference. Masekela was on hand to receive ATS’s World Lung Health Award in recognition of her lengthy career, which includes founding the African Chronic
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Dr. Refiloe Masekela of @patscommunity and @GlobalAsthmaNet was honored at #ATS2025 with the World Lung Health Award🏆. Check out our exclusive video interview. ⬇ @atscommunity @bronchigirl #asthma https://t.co/5nYrbA4h2P
-
-
Mashup Score: 3
The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
New at #ATS2025: ProVENT study findings show that dupilumab (DUPIXENT) for severe #asthma led to long-lasting improvements in asthma control, quality of life, and exacerbations, with remission in over half of those treated within 1 to 2 years.🫁 🔗View: https://t.co/nyTZsc4Rvu
-
-
Mashup Score: 2Socioeconomic Disparities’ Impact on Nutrition and Lung Health, with Lisa G. Wood, PhD - 2 month(s) ago
During her ATS interview, Lisa Wood, PhD, spoke about economic and geographic disparities and their connection to diet and related respiratory health outcomes.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
At #ATS2025, Dr. Lisa G. Wood, known for her research at @HMRIAustralia, discussed socioeconomic & geographic disparities in nutrition and their influence on diet. Also, she highlighted associated risk of conditions such as #asthma in childhood. 🔗 View: https://t.co/IUsv9J9Wj5
-
-
Mashup Score: 5
In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
New at #ATS2025: Dupilumab (DUPIXENT) significantly reduced #asthma exacerbations/improved control in children with moderate-to-severe type 2 asthma, new data suggest, regardless of duration. This was a post-hoc analysis led by @wphipmd. 🔗View summary: https://t.co/gq6ImXHSid
-
-
Mashup Score: 4
This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
New at #ATS2025: A new analysis suggests that, unlike dupilumab, rademikibart does not cause eosinophil elevation in patients with #asthma, highlighting a potential distinction in how the 2 biologics interact with interleukin (IL)-4Rα. View our summary https://t.co/fbNVpSMnRU
-
-
Mashup Score: 3
The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
New at #ATS2025: ProVENT study findings show that dupilumab (DUPIXENT) for severe #asthma led to long-lasting improvements in asthma control, quality of life, and exacerbations, with remission in over half of those treated within 1 to 2 years.🫁 🔗View: https://t.co/nyTZsc4Rvu
-
-
Mashup Score: 2
The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
New at #ATS2025: ProVENT study findings show that dupilumab (DUPIXENT) for severe #asthma led to long-lasting improvements in asthma control, quality of life, and exacerbations, with remission in over half of those treated within 1 to 2 years.🫁 🔗View: https://t.co/nyTZsc4Rvu
-
-
Mashup Score: 4
This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
New at #ATS2025: A new analysis suggests that, unlike dupilumab, rademikibart does not cause eosinophil elevation in patients with #asthma, highlighting a potential distinction in how the 2 biologics interact with interleukin (IL)-4Rα. View our summary https://t.co/fbNVpSMnRU
-
-
Mashup Score: 5
In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
New at #ATS2025: Dupilumab (DUPIXENT) significantly reduced #asthma exacerbations/improved control in children with moderate-to-severe type 2 asthma, new data suggest, regardless of duration. This was a post-hoc analysis led by @wphipmd. 🔗View summary: https://t.co/gq6ImXHSid
-
Dr. Refiloe Masekela of @patscommunity and @GlobalAsthmaNet was honored at #ATS2025 with the World Lung Health Award🏆. Check out our exclusive video interview. ⬇ @atscommunity @bronchigirl #asthma https://t.co/5nYrbA4h2P